Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

The patient recived surgury of nerve-sparing radical hysterectomy.

The patient recived surgury of radical hysterectomy.

Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .

nerve sparing radical hysterectomy

In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.

radical hysterectomy

Cervical cancer in young patients increased significantly in recent years, and early surgical treatment for patients with 5 years of survival rate is as high as 90%, But the traditional extensive hysterectomy (RH) caused by intraoperative pelvic autonomic nerve may damage the bladder and rectum and the incidence of complications such as sexual dysfunction is nearly 25% to 80%, thus seriously affect the patient's quality of life.Pelvic autonomic nerve preservation system of extensive hysterectomy (NSRH) can decrease the complications of above, but at home and abroad mainly adopts pulling the urine tube time, determination methods of residual urine volume, bladder function are studied in only a few scholars urine flow mechanics method is applied to carry on objective appraisal limited cases of postoperative bladder function, and the anorectal function damage ，we can use the anorectal dynamics to get objective index of anorectal function .overall research lack of large sample research of dynamic system. No objective index to evaluate the anorectal function In the early stage of the study, we have conducted about uterine ligament, sacral ligaments and nerve distribution of the bladder cervix vaginal ligament of experimental research, provide the neural anatomy basis for NSRH operation, and based on research for innovative operation scheme is put forward.Proposed on the basis of the above research, this study adopt the internationally used - urine flow mechanics, the method for evaluating the bladder function of NSRH, RH, two kinds of the injured function of bladder surgery patients before and after operation of comparative study, the change of dynamic assessment before and after surgery in patients with bladder function,and the anorectal function dameage and than provide the basis for further treatment.

Nerve Sparing Radical Hysterectomy VS Radical Hysterectomy: Safety and Clinical Efficacy

The Randomized Controlled Trial of Nerve Sparing Hysterectomy Radical Hysterectomy and Radical Hysterectomy

Chen Chunlin

Obstetrics and Gynecology

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Cisplatin

Patients in group A don't receive neoadjuvant chemotherapy

Patients in group B receive neoadjuvant chemotherapy and achieve imaging response

Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy

Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy

Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

Two cycles of neoadjuvant chemotherapy

First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)

First imaging evaluation

Second imaging evaluation consists of pelvic magnetic resonance imaging

Second imaging evaluation

The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).

The third cycles of neoadjuvant chemotherapy

Radiochemotherapy

Pathologic evaluation

Lei Li, M.D.

Lei Li, MD

This cohort study is to evaluate the role of neoadjuvant chemotherapy (NAC) in the treatment of locally advanced cervical cancer (LACC). Sixty patients with LACC (FIGO 2009 stage IB2 to IIB) will be enrolled. After informed consents, they would accept the imaging evaluation of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET). After excluding cases of distant metastasis, they will accept two cycles of NAC (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks). Then a second MRI is performed to evaluate the imaging response. For patients achieving objective response, radical hysterectomy (RH, via laparoscopy or laparotomy) and an evaluation of pathologic response are performed. For patients without objective imaging response, the choice of concurrent chemoradiotherapy or radical hysterectomy will be discussed. After RH, adjuvant therapy will be given according to the RH pathologic results.

The primary objectives consist of (1) the objective imaging response after NAC; (2) the objective pathologic response after RH.

The secondary objectives consist of (1) disease-free survival and overall survival after various therapy modalities; (2) severe adverse effects of NAC; (3) the effects of NAC on the surgical outcomes.

patients diagnosed with locally advanced cervical cancer of stage IB2 to IIB (FIGO 2009 system)

NAC Followed by RH for the Treatment of LACC

Neoadjuvant Chemotherapy Followed by Radical Hysterectomy for the Treatment of Locally Advanced Cervical Cancer: A Prospective Cohort Study

Objective pathologic response for patients with radical hysterectomy

Objective imaging response for patients with neoadjuvant chemotherapy

Disease-free survival for patients with various therapy modalities

Overall survival for patients with various therapy modalities

Severe adverse events of neoadjuvant chemotherapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Nerve Sparing Radical Hysterectomy VS Radical Hysterectomy: Safety and Clinical Efficacy	NCT03069040	Cervical Cancer	nerve sparing r... radical hystere...	20 Years - 70 Years	Southern Medical University, China
NAC Followed by RH for the Treatment of LACC	NCT03963882	Neoadjuvant Che... Locally Advance... Radical Hystere... Objective Respo... Laparoscopy Laparotomy Concurrent Chem... Adjuvant Therap... Systematic Chem...	Two cycles of n... First imaging e... Second imaging ... The third cycle... RH Radiochemothera... Pathologic eval...	18 Years - 45 Years	Peking Union Medical College Hospital
Nerve Sparing Radical Hysterectomy VS Radical Hysterectomy: Safety and Clinical Efficacy	NCT03069040	Cervical Cancer	nerve sparing r... radical hystere...	20 Years - 70 Years	Southern Medical University, China
Nerve Sparing Radical Hysterectomy VS Radical Hysterectomy: Safety and Clinical Efficacy	NCT03069040	Cervical Cancer	nerve sparing r... radical hystere...	20 Years - 70 Years	Southern Medical University, China

Spots Global Cancer Trial Database for rh

Every month we try and update this database with for rh cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for rh

Every month we try and update this database with for rh cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for rh cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.